Age is not the only factor that influences our bones. However, women who are around or past the menopausal age are more prone to bone weakening, increasing the risks of osteoporosis.
Once a procedure becomes routine, it is difficult to replace. However, the NWHN is committed to a vision of osteoporosis care where all women who need it can receive effective screening in order to prevent unnecessary fractures through both medication and non-pharmacologic interventions.
The NWHN acknowledges the overbearing influence pharmaceutical companies have on doctors and patients. This issue arises for those diagnosed with high bone fracture risk. Women are specifically targeted since they’re five times more likely to be diagnosed than men.
The way we screen and treat osteoporosis is still deeply flawed. The NWHN thinks women deserve better, and we’re fighting to make that vision a reality.
Pharmaceutical companies trying to sell drugs have pushed for the adoption of flawed screening techniques that medicalized age-related bone loss. The result? Many healthy women were prescribed osteoporosis drugs despite their serious side effects and risks.